HGH Fragment (176-191) is a modified form of amino acids 176-191 of the HGH polypeptide.
Investigators at Monash University discovered that the fat-reducing effects of HGH appear to be
controlled by a small region near one end of the Hormone molecule. This region, which consists
of amino acids 176-191, is less than 10% of the total size of the HGH molecule and appears to
have no effect on growth or insulin resistance. It works by mimicking the way natural Hormone
regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen
with unmodified Hormone. Like Hormone, HGH fragment 176-191 stimulates lipolysis (the
breakdown or destruction of fat) and inhibits lipogenesis (the transformation of nonfat food
materials into body fat) both in laboratory testing and in animals and humans.
Laboratory Tests and Fat Loss
In laboratory tests on fat cells from rodents, pigs, dogs, and humans, the fragment released fat
specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat
cells, enhanced the burning of fat. In rodents (rats and mice), fragment reduced body fat in obese
animals but, enhanced fat burning without changing food consumption or inducing growth (as it
does not increase IGF levels) or any other unwanted Hormone effect. Research dosages of
500mcg of the HGH fragment 176-191 daily for 30 days did show a reduction of body fat in the
mid abdominal area in both obese, over-weight, and average built people.
HGH Fragment 176-191 as an Active Truncated Peptide
HGH Fragment 176-191 is an analog of the hormone-releasing factor (GRF) which signals the
effects of hormone. It is a 15-mer peptide residue of the C-terminus of HGH to which tyrosine is
added at the N-terminal end. This synthetically produced hormone is very common to weightlifters
and bodybuilders because of a number of physical benefits. Studies claimed that it actually acts
on the reduction of excessive adipose tissues such as those in the abdominal area, increase in
muscle mass, and enhances the lipid content of the body.
These segments of the synthetic peptide 176-191 have been investigated for their in vivo effects
in laboratory mice musculus. Research results have shown that 176-191 have resulted to a short-
period increase in blood glucose and a more sustained increase in plasma insulin, together with
other fragments such as 172-191, 177-191 and 178-191. In addition, the researchers have
suggested that functionality of the peptide depends not only in the informational sequence but
should also have the correct physical configuration. Also, this fragment, being a region of high
accessibility to proteases and also rich in proline, have been demonstrated to affect the
conformational change in the cytoplasmic domain of the band 3 of erythrocyte membrane protein
by serving as the hinge for the pivoting of the two subdomains.
This then suggest that such residue is significant in conformational changes be serving as sites
for peripheral protein binding in some body cells.
In another study on animal subjects, they found out that a 500mcg dosage of the said hormone
increased the lipolytic activity in adipose tissues without having negative influence in the blood
glucose level. Furthermore, though it behaves like a hormone , it does not causes hyperglycemia
because it does not compete with HGH receptors. Because of such effects, researchers have
suggested that it might be used for the elimination of excess abdominal fat which is a significant
aspect of HIV-associated lipodystrophy.
The ( HGH fragment 176-191) exhibits the ability to burn through stubborn adipose tissue, while
increasing energy expenditure, muscle mass, and fat oxidation. All studies have pointed to the
fact that the fragment is an effective treatment for obesity and fat loss, and much safer than its
||HGH 176-191 (2mg)
|PEG MGF (2mg)
||CJC-1295 DAC (2mg)
||GHRP-2 (5mg / 10mg)
||GHRP-6 (5mg / 10mg)
||Melanotan I (10mg)
|Gonadorelin (2mg / 10mg)
||Melanotan II (10mg)
||Follistatin 315 (1mg)
||Follistatin 344 (1mg)